<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03438214</url>
  </required_header>
  <id_info>
    <org_study_id>81226617.8.1001.0065</org_study_id>
    <nct_id>NCT03438214</nct_id>
  </id_info>
  <brief_title>Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients</brief_title>
  <acronym>ETERNITY</acronym>
  <official_title>Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients: Randomized and Controlled Multicenter Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled multicenter clinical trial. The purpose of this study is to
      compare the continuous infusion of vancomycin with intermittent infusion regarding the
      effectiveness to reach the target serum level and the relationship between infusion type and
      nephrotoxicity in critically ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vancomycin is a glycopeptide antimicrobial which has been used for 50 years against
      gram-positive microorganisms and remains effective against multiresistant bacteria as the
      methicillin resistant Staphylococcus aureus (MRSA), the main microorganism causing nosocomial
      infections. Around the world, the continuous infusion of vancomycin has been studied and
      associated with less rate of nephrotoxicity. This is a randomized, controlled multicenter
      clinical trial that will compare continuous infusion with the intermittent vancomycin
      infusion, the relationship between infusion type with rate of nephrotoxicity and the time to
      target therapeutic serum in critically ill patients at the intensive care units of the Cancer
      Institute of the State of Sao Paulo (ICESP) and the Heart Institute (Incor).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 28, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute renal failure</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Acute renal failure stage 1 according criteria AKIN (Acute Kidney Injury Network).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Acute renal failure stages 2 or 3 according criteria AKIN (Acute Kidney Injury Network).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypersensibility reactions with vancomycin</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Skin rash, bronchospasm or anaphylaxis / anaphylactic shock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Therapeutic efficacy with less length of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of treatment with the antimicrobial</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Therapeutic efficacy with less time of treatment with the antimicrobial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Therapeutic efficacy with less length of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Therapeutic efficacy with less mortality rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Gram-Positive Bacterial Infections</condition>
  <condition>Nephrotoxicity</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Vancomycin continuous infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous infusion of vancomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin intermittent infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermittent infusion of vancomycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Continuous infusion</intervention_name>
    <description>Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L</description>
    <arm_group_label>Vancomycin continuous infusion</arm_group_label>
    <other_name>Continuous infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Intermittent infusion</intervention_name>
    <description>Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.</description>
    <arm_group_label>Vancomycin intermittent infusion</arm_group_label>
    <other_name>Intermittent infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Critically ill patients

          -  Treatment with vancomycin

          -  Preserved renal function.

        Exclusion Criteria:

          -  Cystic fibrosis

          -  Chronic renal failure

          -  Acute renal failure

          -  Having received vancomycin in the last 24 hours

          -  Vancomycin hypersensibility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliano P Almeida, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University os São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Estela M de Oliveira, PhD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>University os São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliano P Almeida, professor</last_name>
    <phone>(5511)98149-2592</phone>
    <email>doctorjuliano@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Estela M de Oliveira, PhD student</last_name>
    <phone>(5516)98237-7000</phone>
    <email>estela.oliveira27@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine University os São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01246-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Estela M de Oliveira, investigator</last_name>
      <phone>11 98237 7000</phone>
      <phone_ext>+55</phone_ext>
      <email>estela.oliveira27@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Juliano P Almeida, professor</last_name>
      <phone>11 98149 2592</phone>
      <phone_ext>+55</phone_ext>
      <email>doctorjuliano@yahoo.com.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Juliano P Almeida, MD, PhD</investigator_full_name>
    <investigator_title>Research associate</investigator_title>
  </responsible_party>
  <keyword>Vancomycin infusion</keyword>
  <keyword>critical ill patients</keyword>
  <keyword>MRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

